The 'forgotten' bile acid sequestrants: Is now a good time to remember?

American Journal of Therapeutics

Volumn 14, Issue 6, 2007, Pages 567-580

  Bays, Harold E ^a   Goldberg, Ronald B ^b  

^a LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Bile acid sequestrant; Cholesterol; Coronary heart disease; Diabetes mellitus; Glucose

Indexed keywords

ALPHA TOCOPHEROL; ATORVASTATIN; BILE ACID SEQUESTRANT; CHOLESTYRAMINE PLUS COLESTIPOL; COLESEVELAM; COLESTILAN; COLESTIPOL; COLESTYRAMINE; EZETIMIBE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; METFORMIN; MEVINOLIN; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLACEBO; PRAVASTATIN; RETINOL; ROSIGLITAZONE; SIMVASTATIN; SULFONYLUREA; TOLBUTAMIDE; TORCETRAPIB; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN K GROUP;

ANGINA PECTORIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPEPSIA; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVASCULARIZATION; REVIEW; RISK; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

ANTICHOLESTEREMIC AGENTS; BILE ACIDS AND SALTS; BLOOD GLUCOSE; CHOLESTYRAMINE; CLINICAL TRIALS AS TOPIC; COLESTIPOL; DIABETES MELLITUS, TYPE 2; DNA-BINDING PROTEINS; DYSLIPIDEMIAS; HUMANS; LIPIDS; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 37349045686     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e31815a69fc     Document Type: Review

References (138)

1. Third Report of the National Cholesterol Education Program NCEP. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Adult Treatment Panel III. Final report. Circulation. 2002;106:3143-3421.
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes UKPDS 33. UK Prospective Diabetes Study UKPDS Group. Lancet. 1998;352:837-853.
3. Buse JB. Action to Control Cardiovascular Risk in Diabetes ACCORD Trial: design and methods. Am J Cardiol. 2007;99:S21-S33.
4. Bays HE, Cohen DE. Rationale and design of a prospective clinical trial program to evaluate colesevelam's glucose-lowering effects in patients with type 2 diabetes mellitus. Curr Med Res Opin. 2007;23:1673-1684.
5. Kirk JK, Huber KR, Clinch CR. Attainment of goals from national guidelines among persons with type 2 diabetes: a cohort study in an academic family medicine setting. N C Med J. 2005;66:415-419.
6. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004;291:335-342.
7. Bays H, McKenney J, Davidson M. Torcetrapib/atorvastatin combination therapy. Exp Rev Cardiovasc Ther. 2005;3:789-820.
8. Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med. 2004;350:1505-1515.
9. Clark RW, Sutfin TA, Ruggeri RB, et al. Raising highdensity lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol. 2004;24:490-497.
10. McKenney JM, Davidson MH, Shear CL, et al. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. J Am Coll Cardiol. 2006;48:1782-1790.
11. Tall AR. CETP inhibitors to increase HDL cholesterol levels. N Engl J Med. 2007;356:1364-1366.
12. Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007;356:1304-1316.
13. Kastelein JJ, van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med. 2007;356:1620-1630.
14. Meinert CL, Knatterud GL, Prout TE, et al. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes. 1970;19(Suppl):830.
15. Caulfield MT, O-Brian KD. Cardiovascular safety of oral antidiabetic agents: the insulin secretagogues. Clinical Diabetes. 2002;20:81-84.
16. Miller JL. Rosiglitazone approved for treatment of type 2 diabetes. Am J Health Syst Pharm. 1999;56:1292, 1294.
17. Hodis HN, Mack WJ, Zheng L, et al. Effect of peroxisome proliferator-activated receptor gamma agonist treatment on subclinical atherosclerosis in patients with insulin-requiring type 2 diabetes. Diabetes Care. 2006;29:1545-1553.
18. Verma S, Szmitko PE. The vascular biology of peroxisome proliferator-activated receptors: Modulation of atherosclerosis. Can J Cardiol. 2006;22(Suppl B):12B-17B.
19. Giannini S, Serio M, Galli A. Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity. J Endocrinol Invest. 2004;27:982-991.
20. Roberts AW, Thomas A, Rees A, et al. Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions. Curr Opin Lipidol. 2003;14:567-573.
21. Reynolds K, Goldberg RB. Thiazolidinediones: beyond glycemic control. Treat Endocrinol. 2006;5:25-36.
22. Wang ZH, Luo F, Liu XM. [Effect of PPARgamma agonist rosiglitazone on regression of the atherosclerotic plaques in rabbits.] Yao Xue Xue Bao. 2005;40:1051-1053.
23. Zhao QM, Yan D, Song AL, et al. [Rosiglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice.] Zhonghua Xin Xue Guan Bing Za Zhi. 2005;33:399-404.
24. Levi Z, Shaish A, Yacov N, et al. Rosiglitazone PPAR gamma-agonist. attenuates atherogenesis with no effect on hyperglycaemia in a combined diabetes-atherosclerosis mouse model. Diabetes Obes Metab. 2003;5:45-50.
25. Samaha FF, Szapary PO, Iqbal N, et al. Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome. Arterioscler Thromb Vasc Biol. 2006;26:624-630.
26. Hetzel J, Balletshofer B, Rittig K, et al. Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arterioscler Thromb Vasc Biol. 2005;25:1804-1809.
27. Lautamaki R, Nuutila P, Airaksinen KE, et al. The effect of PPAR gamma-agonism on LDL subclass profile in patients with type 2 diabetes and coronary artery disease. Rev Diabet Stud. 2006;3:31-38.
28. Skyler JS. PROactive: a sad tale of inappropriate analysis and unjustified interpretation. Clinical Diabetes. 2006;24:63-65.
29. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study PROspective pioglitAzone Clinical Trial In macroVascular Events: a randomised controlled trial. Lancet. 2005;366:1279-1289.
30. Wilcox R, Bousser MG, Betteridge DJ, et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive PROspective pioglitAzone Clinical Trial In macroVascular Events 04. Stroke. 2007;38:865-873.
31. Deeg MA, Buse JB, Goldberg RB, et al. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia [published online ahead of print June 26, 2007 as dc 06-1903]. Diabetes Care. 2007.
32. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457-2471.
33. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med. 2007;357:28-38.
34. Psaty BM, Furberg CD. Rosiglitazone and cardiovascular risk. N Engl J Med. 2007;356:2522-2524.
35. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med. 1988;148:36-69.
36. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984;251:351-364.
37. Robertson TL, Kato H, Gordon T, et al. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California. Coronary heart disease risk factors in Japan and Hawaii. Am J Cardiol. 1977;39:244-249.
38. Keys A. Coronary heart disease in seven countries. 1970. Nutrition. 1997;13:250-252.
39. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality. 30 years of follow-up from the Framingham study. JAMA. 1987;257:2176-2180.
40. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356, 222 primary screenees of the Multiple Risk Factor Intervention Trial MRFIT. JAMA. 1986;256:2823-2828.
41. Dayton S, Pearce ML. Prevention of coronary heart disease and other complications of arteriosclerosis by modified diet. Am J Med. 1969;46:751-762.
42. Miettinen M, Turpeinen O, Karvonen MJ, et al. Effect of cholesterol-lowering diet on mortality from coronary heart-disease and other causes. A twelve-year clinical trial in men and women. Lancet. 1972;2:835-838.
43. Hjermann I, Velve BK, Holme I, et al. Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from the Oslo Study Group of a randomised trial in healthymen. Lancet. 1981;2:1303-1310.
44. Arntzenius AC, Kromhout D, Barth JD, et al. Diet, lipoproteins, and the progression of coronary atherosclerosis. The Leiden Intervention Trial. N Engl J Med. 1985;312:805-811.
45. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365-374.
46. Ravnskov U. Cholesterol lowering trials in coronary heart disease: frequency of citation and outcome. BMJ. 1992;305:15-19.
47. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study 4S. Lancet. 1994;344:1383-1389.
48. Bays H, Dujovne C. Colesevelam HCl: a non-systemic lipid-altering drug. Exp Opin Pharmacother. 2003;4:779-790.
49. Davidson M, Dittakavi V, Bandari A, et al. Colesevelam HCl decreases atherosclerosis and may activate reverse cholesterol transport in cholesterol fed rabbits. J Appl Res. 2006;6:4-13.
50. Bays H. Existing and investigational combination drug therapy for high-density lipoprotein cholesterol. Am J Cardiol. 2002;90:30K-43K.
51. Donovan JM, von BK, Setchell KD, et al. Effects of colesevelam HCl on sterol and bile acid excretion in patients with type IIa hypercholesterolemia. Dig Dis Sci. 2005;50:1232-1238.
52. Bandisode MS, Boshell BR. Hypocholesterolemic activity of colestipol in diabetes. Curr Ther Res Clin Exp. 1975;18:276-284.
53. Duntsch G. [Colestipol by hypercholesteremia in diabetics.] Fortschr Med. 1977;95:1492-1496.
54. Bailey WL, Jones MR, Abby S. Colesevelam HCl for the management of type 2 diabetes mellitus: rationale for a clinical trial program. American College of Clinical Pharmacy Annual Meeting; October 26-29, 2006; St. Louis, MO; Abstract.
55. Zieve FJ, Kalin MF, Schwartz SL, et al. Results of the glucose-lowering effect of WelChol study GLOWS: a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther. 2007;29:74-83.
56. Staels B, Kuipers F. Bile acid sequestrants and the treatment of type 2 diabetes mellitus. Drugs. 2007;67:1383-1392.
57. Mitro N, Mak PA, Vargas L, et al. The nuclear receptor LXR is a glucose sensor. Nature. 2007;445:219-223.
58. Efanov AM, Sewing S, Bokvist K, et al. Liver X receptor activation stimulates insulin secretion via modulation of glucose and lipid metabolism in pancreatic beta-cells. Diabetes. 2004;53(Suppl 3):S75-S78.
59. Seo JB, Moon HM, Kim WS, et al. Activated liver X receptors stimulate adipocyte differentiation through induction of peroxisome proliferator-activated receptor gamma expression. Mol Cell Biol. 2004;24:3430-3444.
60. Bays H, Abate N, Chandalia M. Adiposopathy: sick fat causes high blood sugar, high blood pressure, and dyslipidemia. Future Cardiology. 2005;11:39-59.
61. Bays H, Dujovne CA. Adiposopathy is a more rational treatment target for metabolic disease than obesity alone. Curr Atheroscler Rep. 2006;8:144-156.
62. Bays H, Ballantyne C. Adiposopathy: why do adiposity and obesity cause metabolic disease? Future Lipidology. 2006;1:389-420.
63. Bays H, Blonde L, Rosenson R. Adiposopathy: how do diet, exercise, weight loss and drug therapies improve metabolic disease? Exp Rev Cardiovasc Ther. 2006;4:871-895.
64. Bays H. Adiposopathy - defining, diagnosing, and establishing indications to treat 'sick fat': what are the regulatory considerations? US Endocr Dis. 2006;2:January 2007, 12-14.
65. Tontonoz P, Mangelsdorf DJ. Liver X receptor signaling pathways in cardiovascular disease. Mol Endocrinol. 2003;17:985-993.
66. Laffitte BA, Chao LC, Li J, et al. Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc Natl Acad Sci USA. 2003;100:5419-5424.
67. Bays H, Stein EA. Pharmacotherapy for dyslipidaemia - current therapies and future agents. Exp Opin Pharmacother. 2003;4:1901-1938.
68. Jones JD, Chambliss ML. Hypertriglyceridemia and coronary heart disease. Arch Fam Med. 2000;9:189-190.
69. Jones P, Kafonek S, Laurora I, et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia the CURVES study. Am J Cardiol. 1998;81:582-587.
70. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-1278.
71. Bays H. What are the long-term effects of statin therapy? Nature Clinical Practice Cardiovascular Medicine. 2006;3:128-129.
72. Bays H. Statin safety: an overview and assessment of the data - 2005. Am J Cardiol. 2006;97:6C-26C.
73. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-239.
74. Davidson MH. Differences between clinical trial efficacy and real-world effectiveness. Am J Manag Care. 2006;12:S405-S411.
75. Davidson MH, Maki KC, Pearson TA, et al. Results of the National Cholesterol Education NCEP. Program Evaluation Project Utilizing Novel E-Technology NEPTUNE. II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol. 2005;96:556-563.
76. Bays HE, Dujovne CA, McGovern ME, et al. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]. Am J Cardiol. 2003;91:667-672.
77. Bays HE. Extended-release niacin/lovastatin: the first combination product for dyslipidemia. Exp Rev Cardiovasc Ther. 2004;2:485-501.
78. Gagne C, Bays HE, Weiss SR, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol. 2002;90:1084-1091.
79. Bays HE, Ose L, Fraser N, et al. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther. 2004;26:1758-1773.
80. Bays HE, Davidson M, Jones MR, et al. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. Am J Cardiol. 2006;97:1198-1205.
81. Bays H, Rhyne J, Abby S, et al. Lipid-lowering effects of colesevelam HCl in combination with ezetimibe. Curr Med Res Opin. 2006;22:2191-2200.
82. Welchol Product Information. Colesevelam hydrochloride. Available at: www.welchol.com/pdfs/fullPI.pdf. Accessed July 1, 2007.
83. Takeuchi A, Sano N, Takikawa H. Inhibition of ileal bile acid absorption by colestimide. J Gastroenterol Hepatol. 2003;18:548-553.
84. Yamakawa T, Takano T, Utsunomiya H, et al. Effect of colestimide therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemia. Endocr J. 2007;54:53-58.
85. Tasaki H, Miyamoto M, Kubara T, et al. Cross-over trial of intensivemonotherapy with atorvastatin and combined therapy with atorvastatin and colestimide for Japanese familial hypercholesterolemia. Circ J. 2006;70:14-20.
86. Kawashiri MA, Higashikata T, Nohara A, et al. Efficacy of colestimide coadministered with atorvastatin in japanese patients with heterozygous familial hypercholesterolemia FH. Circ J. 2005;69:515-520.
87. Suzuki T, Oba K, Futami-Suda S, et al. Effects of colestimide on blood glucose-lowering activity and body weight in patients with type 2 diabetes and hypercholesterolemia. J Nippon Med Sch. 2007;74:81-84.
88. Suzuki T, Oba K, Futami S, et al. Blood glucose-lowering activity of colestimide in patients with type 2 diabetes and hypercholesterolemia: a case-control study comparing colestimide with acarbose. J Nippon Med Sch. 2006;73:277-284.
89. Date T, Shigematsu T, Kawashita Y, et al. Colestimide can be used as a phosphate binder to treat uraemia in endstage renal disease patients. Nephrol Dial Transplant. 2003;18(Suppl 3):iii90-iii93.
90. Sakurai K, Fukata H, Todaka E, et al. Colestimide reduces blood polychlorinated biphenyl PCB levels. Intern Med. 2006;45:327-328.
91. Mochida Y, Fukata H, Matsuno Y, et al. Reduction of dioxins and polychlorinated biphenyls PCBs. in human body. Fukuoka Igaku Zasshi. 2007;98:106-113.
92. Sakurai K, Todaka E, Saito Y, et al. Pilot study to reduce dioxins in the human body. Intern Med. 2004;43:792-795.
93. Brensike JF, Levy RI, Kelsey SF, et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation. 1984;69:313-324.
94. Blankenhorn DH, Nessim SA, Johnson RL, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233-3240.
95. Cashin-Hemphill L, Mack WJ, Pogoda JM, et al. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA. 1990;264:3013-3017.
96. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
97. Kane JP, Malloy MJ, Ports TA, et al. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA. 1990;264:3007-3012.
98. Watts GF, Lewis B, Brunt JN, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study STARS. Lancet. 1992;339:563-569.
99. Stone NJ, Blum CB. Management of Lipids in Clinical Practice, National Lipid Association: The Lipid Lowering Drugs, 6th ed. Caddo, OK: Professional Communications Inc.; 2006:283-354.
100. Garg A, Grundy SM. Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. Ann Intern Med. 1994;121:416-422.
101. Bays HE, Goldberg RB, Truitt K, et al. Addition of colesevelam HCl to patients with type 2 diabetes mellitus inadequately controlled on a metformin-based therapy improves glycemic control. Poster presentation AACE 16th Annual Meeting and Clinical Congress; Seattle, WA; April 14, 2007.
102. Goldberg RB, Truitt K. Colesevelam HCl improves glycemic control in type 2 diabetes mellitus subjects managed with insulin therapy. American Heart Association Annual Meeting; Poster presentation; Chicago, IL; November 2006.
103. Fonseca V, Rosenstock J, Truitt K, et al. Colesevelam HCl added to sulfonylurea-based therapy in patients with inadequately controlled type 2 diabetes mellitus improves glycemic control. Poster presentation AACE 16th Annual Meeting and Clinical Congress; Seattle, WA; April 14, 2007.
104. Imai Y, Kawata S, Inada M, et al. Effect of cholestyramine on bile acid metabolism in conventional rats. Lipids. 1987;22:513-516.
105. Gustafsson BE, Angelin B, Einarsson K, et al. Influence of cholestyramine on synthesis of cholesterol and bile acids in germfree rats. J Lipid Res. 1978;19:972-977.
106. Thomson AB, Keelan M. Feeding rats diets containing cheno- or ursodeoxycholic acid or cholestyramine modifies intestinal uptake of glucose and lipids. Digestion. 1987;38:160-170.
107. Feldman EB, Watt R, Feldman DS. Conjugated dihydroxy bile salt inhibition of glucose influx in rat jejunum in vitro. Am J Dig Dis. 1977;22:415-418.
108. Garbutt JT, Kenney TJ. Effect of cholestyramine on bile acid metabolism in normal man. J Clin Invest. 1972;51:2781-2789.
109. Brand SJ, Morgan RG. Stimulation of pancreatic secretion and growth in the rat after feeding cholestyramine. Gastroenterology. 1982;83:851-859.
110. Koide M, Okabayashi Y, Otsuki M. Role of endogenous bile on basal and postprandial CCK release in humans. Dig Dis Sci. 1993;38:1284-1290.
111. Gomez G, Upp JR Jr, Lluis F, et al. Regulation of the release of cholecystokinin by bile salts in dogs and humans. Gastroenterology. 1988;94:1036-1046.
112. Koop I, Lindenthal M, Schade M, et al. Role of cholecystokinin in cholestyramine-induced changes of the exocrine pancreas. Pancreas. 1991;6:564-570.
113. Kogire M, Gomez G, Uchida T, et al. Chronic effect of oral cholestyramine, a bile salt sequestrant, and exogenous cholecystokinin on insulin release in rats. Pancreas. 1992;7:15-20.
114. Katsuma S, Hirasawa A, Tsujimoto G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun. 2005;329:386-390.
115. Stoffel M, Duncan SA. The maturity-onset diabetes of the young MODY1. transcription factor HNF4alpha regulates expression of genes required for glucose transport and metabolism. Proc Natl Acad Sci USA. 1997;94:13209-13214.
116. Cariou B, Duran-Sandoval D, Kuipers F, et al. Farnesoid X receptor: a new player in glucose metabolism? Endocrinology. 2005;146:981-983.
117. Cariou B, Staels B. FXR: a promising target for the metabolic syndrome? Trends Pharmacol Sci. 2007;28:236-243.
118. Inoue Y, Yu AM, Yim SH, et al. Regulation of bile acid biosynthesis by hepatocyte nuclear factor 4alpha. J Lipid Res. 2006;47:215-227.
119. De FE, Mitro N, Gilardi F, et al. Coordinated control of cholesterol catabolism to bile acids and of gluconeogenesis via a novel mechanism of transcription regulation linked to the fasted-to-fed cycle. J Biol Chem. 2003;278:39124-39132.
120. Zhang M, Chiang JY. Transcriptional regulation of the human sterol 12alpha-hydroxylase gene CYP8B1: roles of hepatocyte nuclear factor 4alpha in mediating bile acid repression. J Biol Chem. 2001;276:41690-41699.
121. Yamagata K, Daitoku H, Shimamoto Y, et al. Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1. J Biol Chem. 2004;279:23158-23165.
122. Zhang Y, Lee FY, Barrera G, et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci USA. 2006;103:1006-1011.
123. Cariou B, van HK, Duran-Sandoval D, et al. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem. 2006;281:11039-11049.
124. Stayrook KR, Bramlett KS, Savkur RS, et al. Regulation of carbohydrate metabolism by the farnesoid X receptor. Endocrinology. 2005;146:984-991.
125. Ma K, Saha PK, Chan L, et al. Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest. 2006;116:1102-1109.
126. Zhang Y, Lee FY, Barrera G, et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci USA. 2006;103:1006-1011.
127. Holt JA, Luo G, Billin AN, et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev. 2003;17:1581-1591.
128. Lundasen T, Galman C, Angelin B, et al. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J Intern Med. 2006;260:530-536.
129. Fu L, John LM, Adams SH, et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology. 2004;145:2594-2603.
130. Strack AM, Myers RW. Modulation of metabolic syndrome by fibroblast growth factor 19 FGF19? Endocrinology. 2004;145:2591-2593.
131. Brendel C, Schoonjans K, Botrugno OA, et al. The small heterodimer partner interacts with the liver X receptor alpha and represses its transcriptional activity. Mol Endocrinol. 2002;16:2065-2076.
132. Bays H. Adiposopathy, metabolic syndrome, quantum physics, general relativity, chaos and the Theory of Everything. Exp Rev Cardiovasc Ther. 2005;3:393-404.
133. Bays H, Dujovne CA. Adiposopathy is a more rational treatment target for metabolic disease than obesity alone. Curr Atheroscler Rep. 2006;8:144-156.
134. Stulnig TM, Oppermann U, Steffensen KR, et al. Liver X receptors downregulate 11beta-hydroxysteroid dehydrogenase type 1 expression and activity. Diabetes. 2002;51:2426-2433.
135. Cao G, Liang Y, Broderick CL, et al. Antidiabetic action of a liver x receptor agonist mediated by inhibition of hepatic gluconeogenesis. J Biol Chem. 2003;278:1131-1136.
136. Gupta S, Pandak WM, Hylemon PB. LXR alpha is the dominant regulator of CYP7A1 transcription. Biochem Biophys Res Commun. 2002;293:338-343.
137. Kerr TA, Saeki S, Schneider M, et al. Loss of nuclear receptor SHP impairs but does not eliminate negative feedback regulation of bile acid synthesis. Dev Cell. 2002;2:713-720.
138. Shibata S, Hayakawa K, Egashira Y, et al. Roles of nuclear receptors in the up-regulation of hepatic cholesterol 7alpha-hydroxylase by cholestyramine in rats. Life Sci. 2007;80:546-553.